The Science Behind Airway Directed Protection
The early events at the point of contact with a pathogen are critical in determining whether infection is contained or progresses to more severe disease. Ness Therapeutics Inc. is focused on this early window, developing approaches designed to act locally at the point of entry.
The Upper Airway Is the Point of Entry
The nasal cavity and upper airway are the primary entry points for respiratory viruses, where initial viral replication begins and where early host responses are first activated. Intervening at this site provides an opportunity to influence the course of infection before it spreads to the lower respiratory tract.
Early Intervention Changes Outcomes
Once infection progresses beyond the upper airway, disease becomes more difficult to control. Intervening early, at the site of initial exposure, may reduce viral replication, limit transmission, and influence overall disease progression, making the timing of intervention as important as the intervention itself.
A Host-Directed Strategy
Rather than targeting a specific virus, a host-directed approach focuses on activating the body's own natural antiviral defences. This allows for broader applicability across different viruses and reduces dependence on pathogen-specific identification.
The Science That Drives Our Programs
The airway-first, host-directed principles outlined here are what N001 is built on. Every development decision, from route of administration to mechanism of action, stems from this biological rationale. To see how this science translates into programs, explore N001 or view the full Ness pipeline.
Program and Company Updates
Sign up to receive updates on N001's development milestones, regulatory progress, and key program announcements as Ness Therapeutics Inc. advances toward clinical readiness.
